Patents by Inventor Cameron Bell
Cameron Bell has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240026380Abstract: The present disclosure provides a miRNA hairpin that, when processed by a virus-infected cell, increases the therapeutic effectiveness of the virus. The present disclosure also provides a virus encoding such a miRNA hairpin. The present disclosure also provides pre-miRNAs that, when processed by a virus-infected cell, increase extracellular vesicle secretion of the encoded miRNA hairpin by the virus-infected cell.Type: ApplicationFiled: June 28, 2023Publication date: January 25, 2024Inventors: Carolina Solange ILKOW, John Cameron BELL, Victoria Ann MAHER, Briana Livia Rollande SAMSON
-
Publication number: 20240013293Abstract: A system for payment routing programmed to: receive a payment transaction message relating to a putative transaction, the payment transaction message containing putative transaction data identifying an accountholder and a transaction amount corresponding to the putative transaction; input historical transaction data for the accountholder and at least a portion of the transaction amount to a scaled score algorithm to generate scaled scores, each of the scaled scores representing the likelihood of settlement of the putative transaction on a corresponding date and payment rail; output the scaled scores to a merchant in response to the payment transaction message; receive, from the merchant and in response to the output, feedback data for the putative transaction, the feedback data including a date of attempted payment processing for the putative transaction and an indicator of whether the attempted payment processing was completed; and retrain the scaled score algorithm using the feedback data.Type: ApplicationFiled: September 21, 2023Publication date: January 11, 2024Applicant: Mastercard International IncorporatedInventors: Nicholas Bryan Baguley, Serenie Gagon, Natesh Babu Arunachalam, Justin A. Harnish, Cameron Bell, Daniel Roper
-
Publication number: 20240013176Abstract: A system for payment routing programmed to: receive a payment transaction message relating to a putative transaction, the payment transaction message containing putative transaction data identifying an account of an accountholder and a transaction amount corresponding to the putative transaction; input at least some of the putative transaction data to a scaled score algorithm to generate a scaled score representing the likelihood of settlement of the putative payment transaction on a date, the scaled score algorithm including a plurality of components each respectively outputting a value and the scaled score being based on the plurality of values; generate metadata regarding the scaled score by applying a plurality of contribution rules to the values, the metadata comprising significance indicators for the components with respect to the generation of the scaled score; and output the scaled score and the metadata regarding the scaled score in response to the payment transaction message.Type: ApplicationFiled: September 21, 2023Publication date: January 11, 2024Applicant: Mastercard International IncorporatedInventors: Nicholas Bryan Baguley, Serenie Gagon, Natesh Babu Arunachalam, Justin A. Harnish, Cameron Bell, Daniel Roper
-
Publication number: 20240013189Abstract: A system for payment routing programmed to: receive a payment transaction message relating to a putative transaction, the payment transaction message containing putative transaction data identifying an accountholder and a transaction amount corresponding to the putative transaction; input historical transaction data for the accountholder and at least a portion of the transaction amount to a scaled score algorithm to generate scaled scores for corresponding potential settlement dates, each of the scaled scores representing the likelihood of settlement of the putative transaction from an account of the accountholder on the corresponding one of the potential settlement dates; retrieve, from a financial institution corresponding to the account, actual account balances for the account on the corresponding potential settlement dates; and retrain the scaled score algorithm using the actual account balances.Type: ApplicationFiled: September 21, 2023Publication date: January 11, 2024Applicant: Mastercard International IncorporatedInventors: Nicholas Bryan Baguley, Serenie Gagon, Natesh Babu Arunachalam, Justin A. Harnish, Cameron Bell, Daniel Roper
-
Patent number: 11739350Abstract: The present disclosure provides a miRNA hairpin that, when processed by a virus-infected cell, increases the therapeutic effectiveness of the virus. The present disclosure also provides a virus encoding such a miRNA hairpin. The present disclosure also provides pre-miRNAs that, when processed by a virus-infected cell, increase extracellular vesicle secretion of the encoded miRNA hairpin by the virus-infected cell.Type: GrantFiled: April 10, 2019Date of Patent: August 29, 2023Assignee: OTTAWA HOSPITAL RESEARCH INSTITUTEInventors: Carolina Solange Ilkow, John Cameron Bell, Victoria Ann Maher, Briana Livia Rollande Samson
-
Publication number: 20230206242Abstract: A system for payment routing according to a likelihood of settlement. The system includes processors and/or transceivers programmed to receive a payment transaction message relating to a putative payment transaction. The payment transaction message contains putative payment transaction data including a customer identification (ID) for an account and a transaction amount. The system generates a scaled score representing the likelihood of settlement of the putative payment transaction on at least one date for each of a plurality of potential payment rails. Based at least in part on the at least one scaled score for each of the plurality of potential payment rails, the system selects a payment rail from the plurality of payment rails. The system initiates, via the selected payment rail, a payment transaction corresponding to the putative payment transaction.Type: ApplicationFiled: December 22, 2022Publication date: June 29, 2023Applicant: Mastercard International IncorporatedInventors: Nicholas Bryan Baguley, Young Mi Catarina Ban, William Campbell, Wally F. Lo Faro, William Parkinson, Serenie Gagon, Ahmed Hosny, Alexander Liberson, Gayley Woolston, Nicholas A. Thomas, Brett Ragozzine, Daniel Roper, Justin A. Harnish, Abbas Moosavi, Swati Saini, Cameron Bell, Natesh Babu Arunachalam, Shawn J. Mehrhoff
-
Publication number: 20230203532Abstract: Herein is provided a recombinant tumor-selective viral particle comprising a nucleic acid encoding a recombinant polypeptide for directing an extracellular vesicle (EV) to at least one target cell, said recombinant polypeptide comprising: at least one targeting moiety for directing said EV to said at least one target molecule expressed by said at least one target cell; at least one EV-anchoring polypeptide; and at least one intravesicular polypeptide. The viral particle may be from an oncolytic viruses. Recombinant polypeptides for programming EVs to target particular molecules are also provided. Also described are therapeutic EVs for delivering payload polypeptides (and/or cargo molecules) to target cells, e.g., in vaccine or cell-free “CAR-T”-like applications, along with EVs for recruiting immune cells to target cells in EV-mediated BiTE -like applications. Oncolytic viruses may also be engineered to infect tumor cells and shed programmed EVs, yielding additional therapeutic effects.Type: ApplicationFiled: November 27, 2020Publication date: June 29, 2023Inventors: Carlolina Solange ILKOW, John Cameron BELL, Jack Timothy WHELAN, Mathieu François Joseph CRUPI, Jessie Nhan DUONG, Brian Dennis LICHTY, Matthew John ATHERTON, Fuan WANG, Yoanna Poutou PAUMIER, Stephen Donald BOULTON, Mohammadtaha MOHAMMADIAZAD, Ragunath SINGARAVELU
-
Publication number: 20230117616Abstract: Methods, systems, and storage media for searching for products through a social media platform are disclosed. Exemplary implementations may: receive a selection of an item in a post on the social media platform; generate a digital fingerprint of the item in the post; compare the digital fingerprint with a catalog of digital fingerprints; determine a similarity score between the digital fingerprint and individual digital fingerprints of the catalog of digital fingerprints; determine a subset of digital fingerprints that have similarity scores above a threshold, the subset of digital fingerprints corresponding to a subset of items for sale; and cause display of the subset of items for sale through a user interface of the social media platform.Type: ApplicationFiled: October 18, 2021Publication date: April 20, 2023Inventors: Manfredas Zabarauskas, Andrei Dinu-Ionita, Sean Cameron Bell
-
Patent number: 11590184Abstract: Disclosed herein is an oncolytic recombinant Maraba virus whose genome comprises one or more nucleic acid sequences that, in combination, encode an interleukin-12 (IL12) protein or a functional portion thereof. A method for treating a cancer in a patient using the oncolytic recombinant Maraba virus is also disclosed. The present disclosure also provides a tumour cell infected with an oncolytic rhabdovirus whose genome comprises one or more nucleic acid sequences that, in combination, encode an interleukin-12 (IL12) protein or a functional portion thereof, for use as an infected cell vaccine (ICV) for the treatment of a cancer. A method for treating a cancer in a patient using the infected cell vaccine is also disclosed.Type: GrantFiled: August 9, 2017Date of Patent: February 28, 2023Assignee: TURNSTONE LIMITED PARTNERSHIPInventors: Almohanad Alkayyal, Rebecca Auer, John Cameron Bell
-
Publication number: 20210346441Abstract: There is described herein a non-replicating Rhabdovirus-derived particle that lacks the ability to spread between cells while having tropism against immortalized cells. The non-replicating Rhabdovirus-derived particle may have cytolytic tropism against immortalized cells. There is also described a non-replicating Rhabdovirus-derived particle that lacks the ability to spread between cells but has innate and/or adaptive immune-stimulating properties.Type: ApplicationFiled: July 21, 2021Publication date: November 11, 2021Inventors: David Conrad, Cory Batenchuk, Fabrice Leboeuf, John Cameron Bell
-
Patent number: 11110138Abstract: There is described herein a non-replicating Rhabdovirus-derived particle that lacks the ability to spread between cells while having tropism against immortalized cells. The non-replicating Rhabdovirus-derived particle may have cytolytic tropism against immortalized cells. There is also described a non-replicating Rhabdovirus-derived particle that lacks the ability to spread between cells but has innate and/or adaptive immune-stimulating properties.Type: GrantFiled: December 20, 2013Date of Patent: September 7, 2021Assignee: CELVERUM INC.Inventors: David Conrad, Cory Batenchuk, Fabrice Leboeuf, John Cameron Bell
-
Publication number: 20210128706Abstract: There is described a kit for use in inducing an immune response in a mammal, the kit includes: a first virus that expresses MAGEA3, Human Papilloma Virus E6/E7 fusion protein, human Six-Transmembrane Epithelial Antigen of the Prostate protein, or Cancer Testis Antigen 1, or a variant thereof as an antigenic protein and that is formulated to generate an immunity to the protein or variant thereof in the mammal. The kit also includes a Maraba MG1 virus encoding the same antigen, or a variant of the same antigen. The Maraba MG1 virus is formulated to induce the immune response in the mammal. The first virus is immunologically distinct from the Maraba MG1 virus.Type: ApplicationFiled: September 9, 2020Publication date: May 6, 2021Applicant: TURNSTONE LIMITED PARTNERSHIPInventors: David F. STOJDL, John Cameron BELL, Brian LICHTY, Jonathan POL
-
Publication number: 20210032662Abstract: The present disclosure provides a miRNA hairpin that, when processed by a virus-infected cell, increases the therapeutic effectiveness of the virus. The present disclosure also provides a virus encoding such a miRNA hairpin. The present disclosure also provides pre-miRNAs that, when processed by a virus-infected cell, increase extracellular vesicle secretion of the encoded miRNA hairpin by the virus-infected cell.Type: ApplicationFiled: April 10, 2019Publication date: February 4, 2021Inventors: Carolina Solange ILKOW, John Cameron BELL, Victoria Ann MAHER, Briana Livia Rollande SAMSON
-
Patent number: 10660947Abstract: There is described a kit for use in inducing an immune response in a mammal, the kit includes: a first virus that expresses MAGEA3, Human Papilloma Virus E6/E7 fusion protein, human Six-Transmembrane Epithelial Antigen of the Prostate protein, or Cancer Testis Antigen 1, or a variant thereof as an antigenic protein and that is formulated to generate an immunity to the protein or variant thereof in the mammal. The kit also includes a Maraba MG1 virus encoding the same antigen, or a variant of the same antigen. The Maraba MG1 virus is formulated to induce the immune response in the mammal. The first virus is immunologically distinct from the Maraba MG1 virus.Type: GrantFiled: January 16, 2019Date of Patent: May 26, 2020Assignee: TURNSTONE LIMITED PARTNERSHIPInventors: David F. Stojdl, John Cameron Bell, Brian Lichty
-
Patent number: 10646557Abstract: There is described a kit for use in inducing an immune response in a mammal, the kit includes: a first virus that expresses MAGEA3, Human Papilloma Virus E6/E7 fusion protein, human Six-Transmembrane Epithelial Antigen of the Prostate protein, or Cancer Testis Antigen 1, or a variant thereof as an antigenic protein and that is formulated to generate an immunity to the protein or variant thereof in the mammal. The kit also includes a Maraba MG1 virus encoding the same antigen, or a variant of the same antigen. The Maraba MG1 virus is formulated to induce the immune response in the mammal. The first virus is immunologically distinct from the Maraba MG1 virus.Type: GrantFiled: January 16, 2019Date of Patent: May 12, 2020Assignee: TURNSTONE LIMITED PARTNERSHIPInventors: David F. Stojdl, John Cameron Bell, Brian Lichty
-
Patent number: 10604741Abstract: Described herein is a method of enhancing virus replication in permissive cells that express a receptor to FGF2 protein. The method includes administering FGF2 protein or a functional variant thereof and the virus to the permissive cells. An oncolytic virus having a genome that includes an open reading frame that encodes FGF2 protein or a functional variant thereof is also described.Type: GrantFiled: March 13, 2018Date of Patent: March 31, 2020Assignee: TURNSTONE LIMITED PARTNERSHIPInventors: Carolina Solange Ilkow, Fabrice Le Boeuf, John Cameron Bell, Jean-Simon Diallo, Rozanne Arulanandam
-
Publication number: 20190255160Abstract: There is described a kit for use in inducing an immune response in a mammal, the kit includes: a first virus that expresses MAGEA3, Human Papilloma Virus E6/E7 fusion protein, human Six-Transmembrane Epithelial Antigen of the Prostate protein, or Cancer Testis Antigen 1, or a variant thereof as an antigenic protein and that is formulated to generate an immunity to the protein or variant thereof in the mammal. The kit also includes a Maraba MG1 virus encoding the same antigen, or a variant of the same antigen. The Maraba MG1 virus is formulated to induce the immune response in the mammal. The first virus is immunologically distinct from the Maraba MG1 virus.Type: ApplicationFiled: January 16, 2019Publication date: August 22, 2019Inventors: David F. Stojdl, John Cameron Bell, Brian Lichty, Jonathan Pol
-
Publication number: 20190240301Abstract: There is described a kit for use in inducing an immune response in a mammal, the kit includes: a first virus that expresses MAGEA3, Human Papilloma Virus E6/E7 fusion protein, human Six-Transmembrane Epithelial Antigen of the Prostate protein, or Cancer Testis Antigen 1, or a variant thereof as an antigenic protein and that is formulated to generate an immunity to the protein or variant thereof in the mammal. The kit also includes a Maraba MG1 virus encoding the same antigen, or a variant of the same antigen. The Maraba MG1 virus is formulated to induce the immune response in the mammal. The first virus is immunologically distinct from the Maraba MG1 virus.Type: ApplicationFiled: January 16, 2019Publication date: August 8, 2019Inventors: David F. Stojdl, John Cameron Bell, Brian Lichty, Jonathan Pol
-
Patent number: 10363293Abstract: There is described a kit for use in inducing an immune response in a mammal, the kit includes: a first virus that expresses MAGEA3, Human Papilloma Virus E6/E7 fusion protein, human Six-Transmembrane Epithelial Antigen of the Prostate protein, or Cancer Testis Antigen 1, or a variant thereof as an antigenic protein and that is formulated to generate an immunity to the protein or variant thereof in the mammal. The kit also includes a Maraba MG1 virus encoding the same antigen, or a variant of the same antigen. The Maraba MG1 virus is formulated to induce the immune response in the mammal. The first virus is immunologically distinct from the Maraba MG1 virus.Type: GrantFiled: February 20, 2014Date of Patent: July 30, 2019Assignee: Turnstone Limited PartnershipInventors: David F. Stojdl, John Cameron Bell, Brian Lichty, Jonathan Pol
-
Publication number: 20190216868Abstract: Disclosed herein is an oncolytic recombinant Maraba virus whose genome comprises one or more nucleic acid sequences that, in combination, encode an interleukin-12 (IL12) protein or a functional portion thereof. A method for treating a cancer in a patient using the oncolytic recombinant Maraba virus is also disclosed. The present disclosure also provides a tumour cell infected with an oncolytic rhabdovirus whose genome comprises one or more nucleic acid sequences that, in combination, encode an interleukin-12 (IL12) protein or a functional portion thereof, for use as an infected cell vaccine (ICV) for the treatment of a cancer. A method for treating a cancer in a patient using the infected cell vaccine is also disclosed.Type: ApplicationFiled: August 9, 2017Publication date: July 18, 2019Inventors: Almohanad Alkayyal, Rebecca Auer, John Cameron Bell